Cancer Risks for <i>PMS2</i>-Associated Lynch Syndrome

W. ten Broeke, Sanne; M. van der Klift, Heleen; M.J. Tops, Carli; Aretz, Stefan; Bernstein, Inge; D. Buchanan, Daniel; de la Chapelle, Albert; Capellá, Gabriel; Clendenning, Mark; Engel, Christoph; Gallinger, Steven; Gómez, E.; C. Figueiredo, Jane; W. Haile, Robert; L. Hampel, Heather; van Hest, Liselotte; L. Hopper, John; Hoogerbrugge, Nicoline; von Knebel Doeberitz, Magnus; Le Marchand, Loı̈c; G.W. Letteboer, Tom; A. Jenkins, Mark; Lindblom, Annika; M. Lindor, Noralane; R. Mensenkamp, Arjen; Møller, Pål; A. Newcomb, Polly; A.M. van Os, Theo; Pearlman, Rachel; Pineda, Marta; Rahner, Nils; Redeker, E.; J.W. Olderode-Berends, Maran; Rosty, Christophe; K. Schackert, Hans; J. Scott, Rodney; Senter, Leigha; Spruijt, Liesbeth; Steinke‐Lange, Verena; Suerink, Manon; N. Thibodeau, Stephen; J. Vos, Yvonne; Wagner, Anja; Winship, Ingrid; J. Hes, Frederik; F. A. Vasen, Hans; Wijnen, Juul; Nielsen, Maartje; Ko Win, Aung

doi:10.1200/jco.2018.78.4777

Public

Cancer Risks for PMS2-Associated Lynch Syndrome

Published in Journal of Clinical Oncology • Aug 30, 2018

Authors:

Sanne W. ten Broeke

Heleen M. van der Klift

Carli M.J. Tops

Abstract

PURPOSE: Lynch syndrome due to pathogenic variants in the DNA mismatch repair genes MLH1, MSH2, and MSH6 is predominantly associated with colorectal and endometrial cancer, although extracolonic cancers have been described within the Lynch tumor spectrum. However, the age-specific cumulative risk (p...

Subject

Lynch syndrome

Medicine

Cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!